Form 8-K - Current report:
SEC Accession No. 0001104659-26-084627
Filing Date
2026-07-17
Accepted
2026-07-17 16:07:52
Documents
13
Period of Report
2026-07-17
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2620743d1_8k.htm   iXBRL 8-K 30011
2 EXHIBIT 5.1 tm2620743d1_ex5-1.htm EX-5.1 10962
6 GRAPHIC tm2620743d1_ex5-1img01.jpg GRAPHIC 13995
  Complete submission text file 0001104659-26-084627.txt   230846

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tvrd-20260717.xsd EX-101.SCH 3044
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tvrd-20260717_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tvrd-20260717_pre.xml EX-101.PRE 22378
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2620743d1_8k_htm.xml XML 3221
Mailing Address 3 SUGAR CREEK CTR. BLVD. STE 525 SUGAR LAND TX 77478
Business Address 3 SUGAR CREEK CTR. BLVD. STE 525 SUGAR LAND TX 77478 (713) 489-8654
Tvardi Therapeutics, Inc. (Filer) CIK: 0001346830 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36279 | Film No.: 261183806
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)